China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

Wuhan EasyDiagnosis Biomedicine Co., Ltd. and Hzymes Biotechnology Co.,Ltd. have established Shanghai R&D Center.

COVID-19 saliva testing kits that include a novel preservative can also be used to measure microscopic organisms in the mouth, a Rutgers study found. This enables study of the relationship between mouth and lung microbes and the SARS-CoV-2 virus that may allow for the development of new treatments.

Agilent Technologies reported after the close of the market on Monday that its fiscal fourth quarter revenues increased 12 percent year over year.

Now that the Human Genome Project has officially wrapped, an international team of researchers will map the entire collection of proteins in the human body.

The US Food and Drug Administration announced on Friday that it has issued two final orders reclassifying certain hepatitis C diagnostic tests from Class III to Class II. Additionally, it reclassified blood lancet devices from Class I to Class II and Class III.

MEDICA 2021 has nearly 200 Chinese enterprises participated in the exhibition and over 30 IVD companies among them.

Burning Rock Biotech said Thursday that it has entered a strategic partnership with Merck to develop a companion diagnostic for the MET inhibitor tepotinib (Tepmetko) in the mainland China market, using Burning Rock's OncoCompass Target panel.

Roche announced on Thursday that its new Cobas 5800 molecular instrument has received CE marking.

On November 18, Chinese Academy of Sciences (CAS) announced the list of elected academicians of CAS in 2021. According to regulations, 65 academicians and 25 foreign academicians of CAS were elected in 2021.

Wall Street analysts contend that Johnson & Johnson's recent decision to split off the consumer health unit as its own company is likely to boost growth and increase operating margins for the remaining pharmaceutical and medical device segments.